Optimal management of high-risk non-muscle-invasive bladder cancer during the current bacillus Calmette-Guérin (BCG) shortage is challenging.
Although no evidence-based guidelines exist for this specific situation, current management options can be adapted for when BCG supplies are limited or when BCG is unavailable.
Written by:
Mostafid AH, Palou Redorta J, Sylvester R, Witjes JA. Are you the author?
Department of Urology, Royal Surrey County Hospital, Guildford, UK; 2Department of Urology, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain; Headquarters, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Department of Urology, Radboud UMC, Nijmegen, The Netherlands.
Reference: Eur Urol. 2014 Nov 28. pii: S0302-2838(14)01214-7.
doi: 10.1016/j.eururo.2014.11.031
PubMed Abstract
PMID: 25442053